Rituximab and bilateral HSV epithelial keratitis in a patient with mucous membrane pemphigoid
ConclusionsAlthough rituximab is a promising biologic agent for the treatment of autoimmune diseases, it bears the risk of reactivation of viral infections, including the onset of herpes simplex virus keratitis.
Source: Journal of Ophthalmic Inflammation and Infection - Category: Opthalmology Source Type: research
More News: Autoimmune Disease | Cold Sores | Corticosteroid Therapy | Herpes | Opthalmology | Pemphigoid | Rituxan